|Articles|May 20, 2021

Identifying Associated Risk Factors for Persistent Vancomycin Resistant Enterococcal Bacteremia

Author(s)Killian Meara

In-hospital mortality and recurrent bacteremia occurred in 58% and 17% of patients with persistent VRE BSIs.

Enterococcal bloodstream infections (BSIs) that are caused by vancomycin-resistant enterococcus (VRE) have concerned experts due to the limited number of available treatment options, as well as the high rates of mortality.

Risk factors for persistence have been analyzed for Staphylococcus aureus bacteremia, however there have not been any conducted on patients with persistent VRE BSIs.

Investigators from Stanford Health Care, in collaboration with the UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences and the Stanford University School of Medicine, have conducted a study that aimed to identify risk factors associated with persistent VRE BSIs.

The data was presented at the 23rd Annual Making a Difference in Infectious Disease Meeting 2021 virtual sessions.

The single-center, retrospective, case-control study included 108 participants who were admitted to the hospital between 2016-2020 with a VRE BSI. Patients admitted to the study had a persistent case of bacteremia, which was defined as positive blood cultures with VRE for four days or more despite receiving active antibiotic therapy.

Those who had a resolving case of bacteremia, with subsequent blood cultures documented to be negative within 4 days of initiation of active antibiotic therapy were the control arm of the study.

Investigators employed logistic regression to assess risk factors associated with persistent VRE bacteremia.

Results from the study demonstrated that in-hospital mortality and recurrent bacteremia occurred in 58% and 17% of patients in the persistent VRE BSI group, compared to 40% and 6% in the resolving VRE BSI group.

Risk factors for persistent bacteremia were identified as intermittent hemodialysis (p=0.034), pleural fluid as the primary site of infection (p=0.01), high-grade bacteremia (p=0.002), lack of source control (p<0.001), and >72 hours until source control (p=0.007) in the bivariate analysis.

“Persistent VRE BSI was associated with worse clinical outcomes, including a higher incidence of mortality and recurrent bacteremia. Intermittent hemodialysis and pleural fluid as the primary site of infection were identified as risk factors for persistent bacteremia,” the authors wrote. “Management strategies in the persistent bacteremia group were highly heterogenous, highlighting the need for additional research in this area.”


Related to this article

This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.